A group of researchers at Children’s Hospital of Philadelphia (CHOP), in collaboration with Beam Therapeutics, have tested and developed an «off-the-shelf» chimeric antigen receptor T-cell (CART) using base editing, which is designed to allow for precise editing of the CART with less risk of unwanted and unforeseen outcomes that may accompany other editing methods. The CART, known as 7CAR8 and recently described in a paper in the journal Blood, is highly active against T-cell acute lymphoblastic leukemia (T-ALL) in multiple preclinical models. In the setting of relapsed or refractory disease, T-ALL often does not respond to chemotherapy and chance of cure is low. The hope is 7CAR8 will be an effective and life-saving therapy for these patients, if approved.
Developing an allogeneic chimeric antigen receptor T-cell for relapsed or refractory T-ALL using base editing
A group of researchers at Children's Hospital of Philadelphia (CHOP), in collaboration with Beam Therapeutics, have tested and developed an "off-the-shelf" chimeric antigen receptor T-cell (CART) using base editing, which is designed to allow for precise editing of the CART with less risk of unwanted and unforeseen outcomes that may accompany other editing methods. The CART, known as 7CAR8 and recently described in a paper in the journal Blood, is highly active against T-cell acute lymphoblastic leukemia (T-ALL) in multiple preclinical models. In the setting of relapsed or refractory disease, T-ALL often does not respond to chemotherapy and chance of cure is low. The hope is 7CAR8 will be an effective and life-saving therapy for these patients, if approved.